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Falsiﬁ ed medicines 
in Africa
In their letter on falsiﬁ ed medicines in 
Africa (September issue),1 Paul Newton 
and colleagues lament obstacles to 
improving the global supply of drugs, 
especially in unregulated informal 
markets in Africa. We share their 
concerns, but the authors do overlook 
important efforts to curb the flood 
of fake and substandard malaria 
medicines. The US President’s Malaria 
Initiative, for one, is teaming up with 
local police, customs agents, national 
medicines regulatory authorities, 
and drug sellers to help reduce the 
availability of counterfeit drugs in 
informal private sector outlets and 
marketplaces.
The President’s Malaria Initiative 
is working programmatically with 
the US Agency for International 
Development’s Office of Inspector 
General (USAID OIG) to address and 
mitigate availability of counterfeit 
drugs in the market place.2 For example, 
in Benin, in a mostly unregulated 
market in which shop owners and 
street vendors sell drugs, including 
antimalarials, the Initiative is partnering 
with the USAID OIG, local law 
enforcement, and Ministry of Health 
officials to launch an anticounterfeit 
outreach programme by educating 
and incentivising shopkeepers to 
report suspected counterfeit medicine 
networks, while informing consumers 
on the dangers of substandard drugs 
and how to recognise them. Benin is 
the ﬁ rst of several sub-Saharan African 
countries where this initiative will be 
implemented. And, the USAID OIG is 
actively investigating crimes, working 
with local law enforcement agencies 
in several countries, leading to arrests 
and prosecutions. 
In all 19 focus countries in Africa, 
the President’s Malaria Initiative 
is  partnering with national 
medicines regulatory authorities 
to help strengthen local capacities 
regarding drug quality as part of the 
US Government’s overall technical 
assistance towards strengthening 
health systems. The Initiative is 
helping countries improve surveillance 
capacity to better monitor drug 
quality through randomly testing 
drugs commonly found in both the 
private and public sectors,3 including 
mini-laboratory sentinel sites,4,5 and 
pilot activities in collaboration with 
the US Food and Drug Administration 
and their CD-3 device.6
Although we agree that medicines 
regulatory authorities need to 
be strengthened, we are seeing 
important progress.  Recently, 
two national drug reference 
laboratories in sub-Saharan Africa 
received ISO-17025 accreditation—an 
internationally recognised standard 
regarding laboratory competency.7 
These long-term gains represent 
sustainable health systems capacity 
building, enabling partner country 
medicines regulatory authorities to 
perform much needed quality testing. 
The President’s Malaria Initiative 
is providing substantial support to 
countries to improve regulation and 
enforcement capacity of both the 
public and private sectors, and we 
are expanding efforts with partner 
countries to strengthen all areas of 
their pharmaceutical supply chain, 
including forecasting, storage, 
transportation, and inventory 
management.8 
Finally, as a major procurer of 
artemisinin-based antimalarials,9 
the Initiative employs a stringent 
quality assurance and quality control 
strategy, ensuring that only good 
quality drugs are used in support of US 
Government malaria programmes not 
only in sub-Saharan Africa, but also the 
greater Mekong subregion.  
Although there are various 
estimates of the burden of fake drugs, 
WHO believes that fake medicines 
are now a US$75 billion per year 
industry.10 We agree with Newton and 
colleagues that more must be done 
to assure quality of medicines, and 
second their call for an international 
public health convention on the topic. 
